Industry leaders predict that both ex vivo and in vivo CAR T therapy approaches will advance concurrently, improving scalability, cost efficiency, and consistency to expand patient access. This dual-track innovation addresses manufacturing challenges through automation and integrated workflows, ensuring broader commercialization of life-changing therapies.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views23
Ali NematiBlogUI.author_articles
